SV2C and Parkinson disease: However, the pharmacokineticsin rat brain appears unfavorable for the use of [18F]UCB-F to quantify SV2C in vivo. Dunn et al.have reported that SV2C is selectively enriched in the basal ganglia,is disrupted in animal models of PD, and is involved in the modulationof dopamine release.28−31 Therefore, PET tracers for imaging SV2C could be developed as potentialbiomarkers for Parkinson’s disease.